# Early hypocortisolism with persistent remission following osilodrostat in a patient with long-standing Cushing disease

## TL;DR

A patient with Cushing disease experienced early adrenal insufficiency after osilodrostat treatment but achieved long-term remission without further therapy.

## Contribution

Reports an early case of osilodrostat-induced hypocortisolism followed by sustained remission in Cushing disease.

## Key findings

- Osilodrostat caused early-onset adrenal insufficiency in a Cushing disease patient.
- The patient achieved sustained remission and eucortisolism after discontinuing osilodrostat.
- Weight loss and improved diabetes control occurred without ongoing Cushing therapy.

## Abstract

Cushing syndrome is a disorder of endogenous hypercortisolism characterized by increased morbidity and mortality; when surgery is not curative or feasible, medical therapies targeting pituitary adrenocorticotropic hormone or adrenal cortisol production are essential. We report a case of early-onset hypocortisolism and sustained remission following a brief osilodrostat therapy in a 70-year-old woman with Cushing disease who had been treated for many years with pasireotide and metyrapone. Ten days after initiating osilodrostat, she developed clinical signs of adrenal insufficiency and a low morning serum cortisol of 2.8 µg/dL (SI: 76 nmol/L) (reference range 7-25 µg/dL [SI: 193-690 nmol/L]); osilodrostat was discontinued, and glucocorticoid replacement was initiated, remaining glucocorticoid-replacement dependent at low doses for 2 months. Over subsequent follow-up of over 20 months, her 24-hour urinary free cortisol normalized, and she maintained persistent biochemical and clinical eucortisolism off all Cushing therapy, with no relapse of hypercortisolism. She also experienced weight loss of 16.5 kg and marked improvement in diabetes control, enabling discontinuation of insulin and glucagon-like peptide-1 (GLP-1) receptor agonist therapy. This is among the earliest documented cases of osilodrostat-induced hypocortisolism with long sustained hormonal remission after treatment discontinuation, emphasizing the need for early monitoring and prolonged follow-up.